Tropic raises $105M to scale gene-edited bananas amid $25B crop disease threat
What's the deal? UK agri-biotech startup Tropic Biosciences has raised $105 million in an oversubscribed Series C to expand commercial production of its gene-edited banana and rice varieties.
The round was co-led by ForbionDealroom has a profile for this one. Try Dealroom →'s Bioeconomy Fund and CortevaDealroom has a profile for this one. Try Dealroom → via its Catalyst investment platform, with participation from Just ClimateDealroom has a profile for this one. Try Dealroom →, IQ CapitalDealroom has a profile for this one. Try Dealroom →, ABN AmroDealroom has a profile for this one. Try Dealroom →, Invest InternationalDealroom has a profile for this one. Try Dealroom →, Temasek, Five Seasons VenturesDealroom has a profile for this one. Try Dealroom →, and others. Valuation was not disclosed.
Norwich-based Tropic edits crop DNA using CRISPR-based tools without inserting foreign genes — a distinction that has helped it navigate evolving regulations in multiple markets.
Why now? Tropic had a breakout 2025. It launched two first-of-their-kind commercial banana varieties — a non-browning banana named one of TIME Magazine's best inventions of the year, and an extended shelf-life variety that prolongs green life by 12 days. Demand for both has already outstripped supply.
The company also advanced its programme targeting Panama Disease Tropical Race 4 (TR4), a fungal disease threatening the $25 billion global banana industry. Commercial mother plantations are already being established, with deployment expected from 2027.
What could go wrong? Gene editing in food crops still faces an uneven regulatory landscape globally. While governments in the UK, EU, Japan, and elsewhere have been loosening restrictions, key export markets remain cautious, and any regulatory reversal could delay commercialisation. Consumer acceptance of gene-edited food — even without foreign DNA — also varies significantly by market and could limit uptake.
Scaling plant production at the volumes needed to meet demand is also a significant operational challenge for a company still in its early commercial phase.
The signal: Tropic's raise is one of the strongest signals yet that gene-edited crops have crossed from science project to commercial asset class. The investor mix — combining an impact fund (Just Climate), a crop science giant (Corteva), a life sciences specialist (Forbion), and a sovereign wealth fund (Temasek) — reflects how broadly the thesis is now accepted.
Broad agrifood funding has declined in recent years, making a $105 million oversubscribed round all the more notable. As climate pressures intensify and diseases such as TR4 threaten entire crop categories, the case for precision breeding tools that can outpace conventional methods is becoming harder to ignore.
Sources:
Tropic Biosciences
Forbion
AgTechNavigator
Image credit:
Tropic Biosciences
J.V.
